Moderna Drama, WSJ Mansion Section, Genetically Engineered Military Dogs | Thomas Wright, Kyle Schiller, Steven Schwartz

Moderna's cancer-vaccine trial beat Keytruda alone by 42%, below hyped expectations, triggering a leak-driven 26% stock crash.

• Moderna's phishing-timed crash: Phase III cancer vaccine trial (paired with Keytruda) showed 42% relative risk reduction vs. 49% in Phase II, missing elevated expectations; shares fell 26% intraday after Oncology Central leaked embargoed data two days early.
• Retail trader's lucky timing: Influencer "Togi" flipped ~$500k from Moderna calls to puts hours before the leak-driven crash, attributing the trade partly to literal dreams, not disclosed analysis.

Themes, sentiment and reasons are AI-written paraphrases, checked so they never quote an episode. They may contain errors. Not investment advice. Episodes remain the property of their creators.